Fusi, A; Dalgleish, A
(2017)
The importance for immunoregulation for long-term cancer control.
Future Oncol, 13 (18).
ISSN 1744-8301
https://doi.org/10.2217/fon-2017-0085
SGUL Authors: Dalgleish, Angus George Fusi, Alberto
|
PDF
Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
|
![]() |
Microsoft Word (.doc)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (432kB) |
|
![]() |
Other (Figure 1)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (37kB) |
Abstract
Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy. However, still half the patients do not respond to this treatment. In order to increase the therapeutic ratio in melanoma and other cancers, different approaches are under evaluation. Three relevant questions are at the moment driving the research community: how to maximize benefit while minimizing toxicity; how to better identify patients who are more likely to benefit from immunotherapy; how to convert nonresponders into responders. In this review we summarize the most recent findings and we outline the most likely future challenges.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © Angus Dalgleish This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ | ||||||||
Keywords: | NSCLC, atezolizumab, biomarkers, checkpoint inhibitors, immunotherapy, ipilimumab, melanoma, nivolumab, pembrolizumab, Oncology & Carcinogenesis, 1112 Oncology And Carcinogenesis | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||||
Journal or Publication Title: | Future Oncol | ||||||||
ISSN: | 1744-8301 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 | ||||||||
PubMed ID: | 28776411 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/108856 | ||||||||
Publisher's version: | https://doi.org/10.2217/fon-2017-0085 |
Statistics
Actions (login required)
![]() |
Edit Item |